Global Trial Launches to Test Remdesivir with hIVIG in Covid-19
What you – and doctors – should watch for if you have COVID-19
SARS-CoV-2 Antibodies Persist for Months after Infection
Regeneron joins Lilly in seeking emergency OK for COVID-19 antibody
Takeda-led Covid-19 plasma treatment enters clinical trial with first patient
Novavax: CMI Data De-risks NanoFlu Program and Shows Breadth of Immune Activity, Says Analyst
BioNTech, Rentschler Partner For Covid-19 Vaccine Manufacturing
NIH trial testing hyperimmune intravenous immunoglobulin and remdesivir to treat COVID-19
‘Danger molecule’ associated with being obese, female and black in younger adults
An autoimmune-like antibody response is linked with severe COVID-19
Coronavirus antibodies last at least three months after infection, study suggests
Setting a TRAP for pandemic-causing viruses
Boehringer Ingelheim 2020: Steady as they go
Gilead 2020: HIV … and COVID?
Amgen 2020: 40-Year-Old Pioneer
AstraZeneca 2020: Driven by Covid-19
AbbVie 2020: Beyond Humira
Eli Lilly Files For FDA Emergency Use Of COVID-19 Antibody Treatment
Pfizer 2020: Cancer and COVID-19
Roche 2020: Built for innovation
Training our immune systems: Why we should insist on a high-quality COVID-19 vaccine
Roche working “around the clock” to tackle UK test supply problems
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival
Every COVID-19 case seems different; these scientists want to know why
If COVID-19 Antibody 'Cocktails' Become Popular, Sorrento Stock Could Double, Says Analyst
EU Close – Stocks rise on COVID Treatment news and slow stimulus talks, Little reaction to Powell, Oil’s trifecta, Gold softens
How the leading coronavirus vaccines work
Dried blood spot sampling offers inexpensive way to widen access to antibody testing for COVID-19
GSK, Vir cleared to leap into PhIII, angling for a spot in the Covid-19 antibody race led by Lilly, Regeneron
Race for COVID-19 vaccine hots up as EMA begins review of BioNTech/Pfizer jab